EKF Diagnostics acquires Argutus Medical

Thursday, Dec 09 2010 by

EKF Diagnostics Group, the buy and build point of care diagnostics company recently re-launched by Julian Baines and David Evans, has announced its third acquisition. The company is buying Dublin based Argutus Medical Ltd., which specialises in developing biomarkers for organ injury. In the all-paper deal, EKF plans to issue 9.7 million shares at 22.43p to the vendors for a total consideration of £2.2 million.

Argutus, which was spun out of Biotrin International via an MBO in 2008, has discovered and developed a number of diagnostic tests kits for the early detection of kidney, liver and pancreas injury. Following the acquisition, EKF will focus on commercialising point of care diagnostic products for the early detection of kidney damage in diabetics.

Cormac Kilty, Argutus CEO, will join the EKF management team as chief technology officer following the completion of the acquisition.


Disclaimer:  

This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.


Do you like this Post?
Yes
No
0 thumbs up
0 thumbs down
Share this post with friends



EKF Diagnostics Holdings Plc designs, develops, manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company is focused within the In-Vitro Diagnostic devices (IVD) market place. Other services include the servicing and distribution of other company products under separate distribution agreements. The Company operates in the United States, Germany, Poland, Russia, United Kingdom and Ireland. The Company is also a manufacture and distribution of organ injury biomarkers specializing in acute injury to kidneys (AKI), liver and pancreas. In March 2014, EKF Diagnostics Holdings PLC acquired Separation Technology Inc. more »

Share Price (AIM)
35.25p
Change
0.0  0.0%
P/E (fwd)
28.2
Yield (fwd)
n/a
Mkt Cap (£m)
143.7



  Is EKF Diagnostics Holdings fundamentally strong or weak? Find out More »


What's your view on this thread? to Comment Now

 
 
You are feeling neutral

Use the £ sign in front of a ticker to turn £VOD into Vodafone PLC

You can track all @StockoChat comments via Twitter




Stock Picking Tutorial Centre


Related Content
Hybridans Small Cap Wrap
Hybridan's Small Cap Wrap
Imperial Innovations 13th Sep '12


Point of growth
Point of growth
EKF Diagnostics Holdings 23rd Mar '12


ETS2101 maintaining momentum
ETS2101 maintaining momentum
E-Therapeutics 4th Apr


Stock Picking Simplified

Stockopedia takes your stock picking to the next level with cutting edge Stock Reports & Screening tools.


Get started
or Take a Tour to find out more.